Doug Kass

 Doug Kass is the president of Seabreeze Partners Management Inc. Until 1996, he was senior portfolio manager at Omega Advisors, a $6 billion investment partnership. Before that he was executive senior vice president and director of institutional equities of First Albany Corporation and JW Charles/CSG. He also was a General Partner of Glickenhaus & Co., and held various positions with Putnam Management and Kidder, Peabody. Kass received his bachelor's from Alfred University, and received a master's of business administration in finance from the University of Pennsylvania's Wharton School in 1972. He co-authored "Citibank: The Ralph Nader Report" with Nader and the Center for the Study of Responsive Law and currently serves as a guest host on CNBC's "Squawk Box."

 

 

----------

 

A Note from Doug: Current strategies and actionable trade ideas -- all on one dynamic platform built exclusively for active trades. From sudden sell-offs to sudden spikes, Real Money Pro arms you with crucial analysis -- at a rapid fire, professional pace -- to help you make sound trading decisions -- every day, every hour, and every minute. Join me and my team of professional traders for unique perspectives and breakthrough investment opportunities.

 

Try it Now! Free for 14 Days.

 

Recent Articles By The Author

Raising the White Flag on Allergan: Best of Kass

Raising the White Flag on Allergan: Best of Kass

In highlights from this week's trading diary and posts, Kass finally just gives up on Allergan.

Allergan Stock's Free Fall Offers 10 Important Investing Lessons

Allergan Stock's Free Fall Offers 10 Important Investing Lessons

On Thursday, Doug Kass waved the white flag and exited his AGN position. Here's why.

Allergan's Drop Provides 10 Important Investing Lessons

Allergan's Drop Provides 10 Important Investing Lessons

On Thursday, I waved the white flag exited my AGN position.

This Allergan Bull Reluctantly Waves the White Flag and Exits the Stock

This Allergan Bull Reluctantly Waves the White Flag and Exits the Stock

Looking ahead, Allergan may be more vulnerable than suggested by management or believed by analysts.

Celgene Disappoints; How to Praise, How to Blame: Doug Kass' Views

Celgene Disappoints; How to Praise, How to Blame: Doug Kass' Views

Doug Kass shares his thoughts on Celgene and also explains how bother praise and criticism should be handed out.

Twitter; Risk Appetites: Doug Kass' Views

Twitter; Risk Appetites: Doug Kass' Views

Doug Kass shares his thoughts on Twitter, buying calls, and timeframes and risk appetites.

Big Opportunities to Buy Stocks Have Secretly Emerged

Big Opportunities to Buy Stocks Have Secretly Emerged

The stock market has had a wild week. Some interesting opportunities may have finally emerged.

5 Reasons Why I'm Shorting Caterpillar Stock

5 Reasons Why I'm Shorting Caterpillar Stock

CAT shares fell dramatically on 2 similar looking occasions.

Sticking With Amgen; P&G Doesn't Impress: Doug Kass' Views

Sticking With Amgen; P&G Doesn't Impress: Doug Kass' Views

Doug Kass shares his thoughts on Amgen and Procter & Gamble.

Putting Off the Inevitable; More on the FANG Front: Doug Kass' Views

Putting Off the Inevitable; More on the FANG Front: Doug Kass' Views

Doug Kass shares his thoughts on the inevitable and also discusses FANG.